All In Biotech

Drug Trial Radar · NCT07661056

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 26, 2026

Primary completion

Jan 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

Conditions

  • Graves Disease

Interventions

  • BHV-1300Drug

    delivered subcutaneously via autoinjector

  • PlaceboDrug

    delivered subcutaneously via autoinjector

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants on BHV-1300 vs placebo who are not on an antithyroid drug and with normal thyroid function (total T3, free T4 (FT4), & TSH within normal limits) at Week 26.Time frame: Week 26

Locations

63 sites in 3 countries. Site status is shown where the registry gives one.

  • Site-044

    Tucson, Arizona · Recruiting

  • Site-032

    Burbank, California · Recruiting

  • Site-062

    Huntington Beach, California · Recruiting

  • Site-056

    La Jolla, California · Recruiting

  • Site-048

    Oakland, California · Recruiting

  • Site-006

    San Diego, California · Recruiting

  • Site-078

    South Gate, California · Recruiting

  • Site-067

    Walnut Creek, California · Recruiting

  • Site-035

    Washington D.C., District of Columbia · Recruiting

  • Site-052

    Doral, Florida · Recruiting

  • Site-066

    Fort Myers, Florida · Recruiting

  • Site-019

    Hialeah, Florida · Recruiting

  • Site-027

    Hollywood, Florida · Recruiting

  • Site-061

    Miami, Florida · Recruiting

  • Site-059

    Palm Beach Gardens, Florida · Recruiting

  • Site-074

    Tampa, Florida · Recruiting

  • Site-029

    Atlanta, Georgia · Recruiting

  • Site-053

    Fayetteville, Georgia · Recruiting

  • Site-031

    Champaign, Illinois · Recruiting

  • Site-068

    Oak Brook, Illinois · Recruiting

  • Site-080

    Springfield, Illinois · Recruiting

  • Site-025

    Lenexa, Kansas · Recruiting

  • Site-070

    Baton Rouge, Louisiana · Recruiting

  • Site-046

    Farmington Hills, Michigan · Recruiting

  • Site-004

    Kansas City, Missouri · Recruiting

  • Site-015

    St Louis, Missouri · Recruiting

  • Site-072

    Las Vegas, Nevada · Recruiting

  • Site-047

    Albuquerque, New Mexico · Recruiting

  • Site-077

    Orchard Park, New York · Recruiting

  • Site-038

    Asheville, North Carolina · Recruiting

  • Site-011

    Greenville, North Carolina · Recruiting

  • Site-063

    Morehead City, North Carolina · Recruiting

  • Site-064

    Morehead City, North Carolina · Recruiting

  • Site-039

    Raleigh, North Carolina · Recruiting

  • Site-033

    Statesville, North Carolina · Recruiting

  • Site-045

    Wilmington, North Carolina · Recruiting

  • Site-008

    Canton, Ohio · Recruiting

  • Site-021

    Cincinnati, Ohio · Recruiting

  • Site-037

    Norman, Oklahoma · Recruiting

  • Site - 012

    Philadelphia, Pennsylvania · Recruiting

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.